Probiotics and health: New facts and ideas

Current Opinion in Biotechnology

Volumn 13, Issue 5, 2002, Pages 486-489

  Marteau, Philippe ^a   Seksik, Philippe ^a   Jian, Raymond ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; INTERLEUKIN 10; MESALAZINE; PROBIOTIC AGENT; SUPEROXIDE DISMUTASE; TOLL LIKE RECEPTOR; TREFOIL PEPTIDE; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; VSL 3;

ALLERGY; ATOPIC DERMATITIS; BIFIDOBACTERIUM; BIFIDOBACTERIUM ANIMALIS; CLINICAL TRIAL; DENDRITIC CELL; DNA METHYLATION; DNA MODIFICATION; DRUG EFFECT; DRUG EFFICACY; ENTERITIS; ESCHERICHIA COLI; GASTROINTESTINAL TRACT; HEALTH; HUMAN; ILEITIS; IMMUNOMODULATION; IMMUNOSTIMULATION; INTESTINE FLORA; INTESTINE INFECTION; LACTOBACILLUS; LACTOBACILLUS DELBRUECKII; LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS; METHODOLOGY; NONHUMAN; PANCREAS INSUFFICIENCY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; STAPHYLOCOCCUS HYICUS; STREPTOCOCCUS THERMOPHILUS; ULCERATIVE COLITIS;

BACTERIA (MICROORGANISMS); BIFIDOBACTERIUM; BIFIDOBACTERIUM ANIMALIS; ESCHERICHIA COLI; LACTOBACILLUS; LACTOBACILLUS DELBRUECKII; LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS; LOTUS; STAPHYLOCOCCUS; STAPHYLOCOCCUS HYICUS; STREPTOCOCCUS; STREPTOCOCCUS THERMOPHILUS;

EID: 0036812090     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(02)00368-3     Document Type: Review

References (30)

1. Dunne C., Murphy L., Flynn S., O'Mahony L., O'Halloran S., Feeney M., Morrissey D., Thornton G., Fitzgerald G., Daly C., et al. Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie Van Leeuwenhoek. 76:1999;279-292.
2. Marteau P.R., Vrese M.D., Cellier C.J., Schrezenmeir J. Protection from gastrointestinal diseases with the use of probiotics. Am J Clin Nutr. 73:2001;430S-436S.
3. Hooper L.V., Wong M.H., Thelin A., Hansson L., Falk P.G., Gordon J.I. Molecular analysis of commensal host-microbial relationships in the intestine. Science. 291:2001;881-884. This paper shows that commensal bacteria modulate the expression of some of the host genes involved in several important intestinal functions, including mucosal barrier fortification. These findings provide perspectives about the interactions between resident or ingested microorganisms and their hosts.
4. Christensen H.R., Frokiaer H., Pestka J.J. Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J Immunol. 168:2002;171-178.
5. Rachmilewitz D., Karmeli F., Takabayashi K., Hayashi T., Leider-Trejo L., Lee J., Leoni L.M., Raz E. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology. 122:2002;1428-1441. Immunostimulatory DNA sequences (ISS-DNA) from bacteria were shown for the first time to decrease inflammation in several models of inflammatory bowel disease in rodents (dextran sodium sulfate-induced colitis and hapten-induced colitis in Balb c mice, and spontaneous colitis occurring in IL-10 knockout mice). The ISS-DNA inhibited the induction of colonic proinflammatory cytokines and chemokines and suppressed the induction of colonic matrix metalloproteinases. As the gastrointestinal tract, especially the ileum and the colon, is exposed to bacterial DNA, these findings suggest a physiological, anti-inflammatory role for immunostimulatory DNA from endogenous bacteria in the gastrointestinal tract.
6. Rachmilewitz D, Karmeli F, Takabayashi K, Hayashi T, Raz E: Amelioration of experimental colitis by probiotics is due to the immunostimulatory effect of its DNA. Gastroenterology 2002, 122:abstract T1004.
7. Madsen K, Jijon H, Yeung H, McKaigney C, De Simone C: DNA from probiotic bacteria exerts anti-inflammatory actions on epithelial cells by inhibition of NFκB. Gastroenterology 2002, 122:abstract 546.
8. Gionchetti P., Rizzello F., Venturi A., Brigidi P., Matteuzzi D., Bazzocchi G., Poggioli G., Miglioli M., Campieri M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 119:2000;305-309. A well-designed double-blind placebo-controlled study showing that a probiotic preparation is very effective in the treatment of chronic relapsing pouchitis (an inflammatory bowel disease that occurs in humans after ileoanal anastomosis and in which the endogenous flora is thought to have a role).
9. Mimura T, Rizzello F, Schreiber S, Talbot IC, Nicholls R, Gionchetti P, Campieri M, Kamm M: Once daily high dose probiotic therapy maintains remission and improved quality of life in patients with recurrent or refractory pouchitis: a randomized, placebo-controlled double-blind trial. Gastroenterology 2002, 122:abstract 667.
10. Ulisse S., Gionchetti P., D'Alo S., Russo F.P., Pesce I., Ricci G., Rizzello F., Helwig U., Cifone M.G., Campieri M., De Simone C. Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am J Gastroenterol. 96:2001;2691-2699.
11. Gionchetti P., Rizzello F., Venturi A., Helwig U., Amadini C., Lammers K.M., Ugolini F., Poggioli G., Campieri M. Prophylaxis of pouchitis onset with probiotic therapy: a double blind, placebo controlled trial. Gastroenterology. 118:2000;G1214.
12. Kruis W., Schutz E., Fric P., Fixa B., Judmaier G., Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 1:1997;853-858.
13. Rembacken B.J., Snelling A.M., Hawkey P.M., Chalmers D.M., Axon A.T. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 354:1999;635-639.
14. Kruis W., Fric P., Stolte M. Mutaflor study group: Maintenance of remission in ulcerative colitis is equally effective with Escherichia coli Nissle 1917 and with standard mesalamine. Gastroenterology. 120:2001;A139.
15. Isolauri E., Arvola T., Sutas Y., Moilanen E., Salminen S. Probiotics in the management of atopic eczema. Clin Exp Allergy. 30:2000;1604-1610.
16. Kalliomaki M., Salminen S., Arvilommi H., Kero P., Koskinen P., Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet. 357:2001;1076-1079. This double-blind randomized placebo-controlled study shows that probiotic administration in mothers before birth, during lactation and in infants significantly decreases the risk of developing atopic eczema in the first two years of life. This result is in keeping with the theory that an excessive hygiene (or a too low bacterial priming of the immune system) in infancy is associated with an increased risk of allergy.
17. Rautava S., Kalliomaki M., Isolauri E. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol. 109:2002;119-121.
18. Kirjavainen P.V., Apostolou E., Arvola T., Salminen S.J., Gibson G.R., Isolauri E. Characterizing the composition of intestinal microflora as a prospective treatment target in infant allergic disease. FEMS Immunol Med Microbiol. 32:2001;1-7.
19. Apostolou E., Pelto L., Kirjavainen P.V., Isolauri E., Salminen S.J., Gibson G.R. Differences in the gut bacterial flora of healthy and milk-hypersensitive adults, as measured by fluorescence in situ hybridization. FEMS Immunol Med Microbiol. 30:2001;217-221.
20. Helin T., Haahtela S., Haahtela T. No effect of oral treatment with an intestinal bacterial strain, Lactobacillus rhamnosus (ATCC 53103), on birch-pollen allergy: a placebo-controlled double-blind study. Allergy. 57:2002;243-246. This paper shows that L. rhamnosus GG is not effective in every case of allergy, as no effect was observed in adults or teenagers with birch pollen and apple allergy.
21. Coconnier M.H., Lievin V., Hemery E., Servin A.L. Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB. Appl Environ Microbiol. 64:1998;4573-4580.
22. Cremonini F., Canducci F., Di Caro S., Santarelli L., Armuzzi A., Gasbarrini G., Gasbarrini A. Helicobacter pylori treatment: a role for probiotics? Dig Dis. 19:2001;144-147.
23. Sakamoto I., Igarashi M., Kimura K., Takagi A., Miwa T., Koga Y. Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. J Antimicrob Chemother. 47:2001;709-710.
24. Felley C.P., Corthesy-Theulaz I., Rivero J.L., Sipponen P., Kaufmann M., Bauerfeind P., Wiesel P.H., Brassart D., Pfeifer A., Blum A.L., Michetti P. Favourable effect of an acidified milk (LC-1) on Helicobacter pylori gastritis in man. Eur J Gastroenterol Hepatol. 13:2001;25-29.
25. Mukai T., Asasaka T., Sato E., Mori K., Matsumoto M., Ohori H. Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol Med Microbiol. 32:2002;105-110.
26. Vesa T.H., Marteau P., Korpela R. Lactose intolerance. J Am Coll Nutr. 19:(Suppl. 2):2000;165S-175.
27. Drouault S., Juste C., Marteau P., Renault P., Corthier G. Oral treatment with Lactococcus lactis expressing Staphylococcus hyicus lipase enhances lipid digestion in pigs with induced pancreatic insufficiency. Appl Environ Microbiol. 68:2002;3166-3168. This paper shows that bacteria that are lysed by bile in the upper small intestine may be used to transport enzymes and cure disease. L. lactis that was genetically modified to contain high levels of lipase helped lipiddigestion in a pig model with pancreatic insufficiency. Clinical applications can be expected, especially in patients with cystic fibrosis and insufficient response to classical pancreatic enzyme supplementation. Genetically modified probiotics could constitute new treatment strategies.
28. Sidhu H., Allison M.J., Chow J.M., Clark A., Peck A.B. Rapid reversal of hyperoxaluria in a rat model after probiotic administration of Oxalobacter formigenes. J Urol. 166:2001;1487-1491.
29. Pouwels P.H., Vriesema A., Martinez B., Tielen F.J., Seegers J.F., Leer R.J., Jore J., Smit E. Lactobacilli as vehicles for targeting antigens to mucosal tissues by surface exposition of foreign antigens. Methods Enzymol. 336:2001;369-389.
30. Steidler L., Hans W., Schotte L., Neirynck S., Obermeier F., Falk W., Fiers W., Remaut E. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science. 289:2000;1352-1355.